Search Results for “EC” – Page 147

Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in the initial (first-line) treatment of people with advanced squamous non-small cell lung cancer (NSCLC). Safety for the TECENTRIQ and chemotherapy combination appeared consistent with the known safety profile of the individual medicines, and no new safety signals were identified with the combination. At this interim analysis a statistically significant overall survival (OS) benefit was not observed and the study will continue as planned. These data will be presented at an upcoming oncology congress.

Source: cleveland19
731
March 22, 2018

New AI technique dramatically improves the quality of medical imaging

AUTOMAP offers a number of potential benefits for clinical care, even beyond producing high-quality images in less time with MRI or with lower doses with X-ray, CT and PET. Because of its processing speed, the technique could help in making real-time decisions about imaging protocols while the patient is in the scanner.

Source: Artificial Intelligence Research
478
March 22, 2018

AI imaging machine learning Researches

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors;

Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhibitor of RIPK1 in a Phase 1 clinical trial in healthy volunteers and achieved proof of concept of its large molecule blood-brain barrier delivery platform technology in nonhuman primates.

Source: Nasdaq
554
March 21, 2018

Clinical Trial neurodegenerative disease RIPK1

NHS and digital health firms must improve cybersecurity

The NHS and digital health companies must learn from other industries to secure devices and systems against cyber attacks, according to a new report.

Source: PharmaPhorum
691
March 21, 2018

cybersecurity NHS Policies

UNITY Biotechnology, Inc. Completes $55 Million Series C Financing

UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced the closing of a $55 million Series C financing.

Source: prnewswire
691
March 21, 2018

aging Market Views Series

Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)

Bayer reported that the Chinese Food and Drug Administration (CFDA) approved Stivarga (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib) (Press release, Bayer, DEC 13, 2017, View Source [SID1234522618]).

Source: 1stoncology
530
March 20, 2018

HCC New Approvals Nexavar® Stivarga®

Blockchain medical device set to improve the delivery for babies born by C-section

NnBu Holdings has developed a blockchain medical device to help deliver healthy outcomes for babies born by C-section.

Source: Open Access Government
656
March 19, 2018

blockchain digital health Researches

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program (AAV-CLN1), an AAV-based gene therapy for the treatment of CLN1 disease (infantile and late infantile onset Batten disease).

Source: Tmcnet
430
March 19, 2018

CLN1 disease lysosomal storage New Approvals

Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported interim clinical data of BPX-501 in pediatric patients with acute myeloid leukemia (AML) and primary immunodeficiencies (PIDs). BPX-501 is an adjunct T cell therapy incorporating CaspaCIDe® administered after haploidentical hematopoietic stem cell transplant (haplo-HSCT) for the treatment of hematologic cancers and inherited blood diseases.

Source: ir.bellicum
545
March 19, 2018

AML BPX-501 Clinical Trials PIDs T cell therapy

Preview — Global Pharmaceutical and Medical Device Exhibitions in the Second Quarter of 2018

Have you prepared for all the exhibitions you want to attend in the second quarter of 2018? Ddu, the leading global pharmaceutical & medical device B2B online platform, plans to attend a number of major international pharmaceutical and medical device exhibitions in the second quarter of this year. Here is a summary of each event:

Source: Ddu
149,458
March 16, 2018

Exhibitions & Activities medical device pharmaceutical

Phase III IMpower131 Study Showed Genentechs TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer

New AI technique dramatically improves the quality of medical imaging

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors;

NHS and digital health firms must improve cybersecurity

UNITY Biotechnology, Inc. Completes $55 Million Series C Financing

Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)

Blockchain medical device set to improve the delivery for babies born by C-section

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease

Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501

Preview — Global Pharmaceutical and Medical Device Exhibitions in the Second Quarter of 2018

Trending Topics

Hot Tags

Subscribe

more

more

Customer Services

About Us

Buy on Drugdu.com

Sell on Drugdu.com

Blogroll

Free APP

Follow Us